Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20240403016
- Term of Validity
- 3 April 2024 - 3 April 2025
- Company's Country
- Germany
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The German SME is specialised in the development, production and marketing of innovative in-vitro diagnostics in the fields of transfusion medicine and immunohaematology. They have extensive expertise in molecular biology techniques, like PCR and sequencing, as well as data analysis and software integration. The company offers its expertise with a view to join a Horizon Europe Cluster 1 Call, Eurostars or similar proposals under a research and development cooperation agreement.
- Full Description
-
The German company was founded in 1998 and is an internationally active company with currently around 50 employees and an annual turnover of 5 million euros. It has excellent experience in the development, production and worldwide marketing of innovative quality in-vitro diagnostics for the fields of transfusion medicine and immunohaematology.
The company has extensive expertise in standard PCR methods, real-time PCR and DNA sequencing on Illumina and Oxford Nanopore plattforms. Additionally, they have comprehensive expertise in data analysis and software integration.
It is a supplier of a complete product line in the field of human leucocyte antigens (HLA) and the world's first provider of self-produced PCR genotyping assays for blood group typing. The product range extends from DNA isolation and test detection (PCR or sequencing) to data analysis in an user-friendly software. Moreover, they are the only provider worldwide for the complete method range of serology, SSP, real-time and NGS.
The company has a complete quality management system (ISO-certified). The above-mentioned products are CE-certified and also fulfil the additional requirements of Annex 2 of the IVD Directive for transfusion medicine products.
The company has excellent knowledge in acquiring federal third-party funds and acts regularly as a consortium leader. It has been involved in several federal third-party funded projects with its expertise in PCR and sequencing with the aim to open up new business areas, e.g. bacterial detection, prenatal diagnostics, immunology.
The German company specialized in innovative diagnostic solutions with smart software integration in the field of PCR and sequencing is interested in joining national consortia as well as international ones, like Ira-SME or Eurostars. They are especially looking forward to join an Horizon Europe Cluster 1 consortium under a research and development agreement.
Their added value: They could bring in expertise in molecular biology techniques, like PCR and sequencing, as well as data analysis and software integration. The company can contribute a whole platform, from DNA isolation, PCR and data analysis. - Advantages and Innovations
-
- The company provides core R&D expertise in planning and execution of projects.
- They have an excellent knowledge in primer and probe design for qPCR applications as well as primer design on a high multiplex level for amplification-based sequencing approaches.
- They have experience in using whole blood or plasma as a template for DNA amplification without purification, as well as RT-qPCR or isothermal amplification.
- Their knowledge also includes the sequencing of DNA (amplificate-based) and RNA (single cell sequencing) on an Illumina, as well as Oxford Nanopore sequencing device.
- Furthermore, they have extensive know-how in the establishment of Allele data bases used for the assay design as well as for the data analysis.
- Another strength of the company is their knowledge in software-based data analysis.
- PCR data are analyzed in a commercial company owned software.
- Another commercially available company owned software is used to analyze long-range (several kilobases) as well as short-range (several hundred bases) sequenced fragments. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 9: Industry, Innovation and InfrastructureGoal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
The company is looking for project partners to work together in federal, as well as international third-party funded projects. They are especially looking for a coordinator or project team to jointly apply for a Horizon Europe Cluster 1 call.
They are looking for projects which can result in diagnostic products in a variable field. Regardless of that, they are very open to expand their existing expertise which can lead to new diagnostics in the long term run.
In the field of PCR this could be e.g. to improve their knowledge of direct PCR from different raw materials (like saliva, swabs or filter paper as examples) or using different PCR methods (like isothermal amplification, RT-PCR or dPCR).
In the sequencing field they would love to expand their existing knowledge in different directions, e.g. bacterial sequencing, whole genome sequencing, single cell sequencing, sequening out of difficult sample materials, like FFPE samples, among others.
Another focus of interest is to expand the functions of their PCR and sequencing data analysis softwares, as well as digitalize developmental or manufactural steps by establishing software tools for e.g. an AI-driven primer design or allele database generation. - Type and Size of Partner
- OtherR&D InstitutionUniversityBig companySME <=10SME 50 - 249SME 11-49
- Type of partnership
- Research and development cooperation agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 06001009 - Gene - DNA Therapy06002009 - Molecular design06002002 - Cellular and Molecular Biology01003010 - Databases, Database Management, Data Mining06001005 - Diagnostics, Diagnosis
- Market keywords
- 04009 - In vitro Testing, Trials04006 - Cellular and Molecular Biology05001002 - In-vitro diagnostics04001003 - Medical genetic engineering applications05001005 - Molecular diagnosis
- Sector Groups Involved
- Health
- Targeted countries
- All countries